AZ replants R&D roots in China, goes all-in on innovation

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation.

As MNCs twist and turn on how best to participate in China’s growing biopharma sector and tap its increasingly important market, AstraZeneca plc (LSE:AZN; NYSE:AZN) is charting a different course from some its peers...